Gabapentinoids are frequently used in the management of cancer pain. In recent Cochrane systematic reviews, although there was an abundance of evidence relating to non-cancer pain, only a few studies related to cancer pain. This review summarizes recent randomised controlled trials (RCTs) evaluating the use of gabapentinoids for tumour-related (as monotherapy or part of combination therapy) and treatmentrelated pain.
INTRODUCTION
The prevalence of pain in patients with cancer is over 50% [1] . Pain is often of moderate-to-severe intensity [2] and can be related to the tumour itself, cancer treatments, or comorbid conditions [3] . The WHO three-step analgesic ladder recommends the use of escalating analgesics (non-opioids to mild then strong opioids) with the use of adjuvants at each stage to achieve optimal pain control [4] .
Gabapentinoids (gabapentin and pregabalin) are anti-epileptic drugs and adjuvants used in pain management. They bind to the a2d subunit of presynaptic N, P/Q type voltage-gated calcium channels [5] in the spinal dorsal horn [6] , causing reduced cell-surface expression [7] , and subsequent reduction in calcium influx and neurotransmitter release [6, 8] . a2d subunit upregulation has been found in neuropathic pain and persistent inflammatory states [9] [10] [11] . Gabapentinoids also affect descending inhibitory pathways by reducing GABA transmission in the locus coeruleus [6, 12, 13] . Table 1 [14] provides further details about their pharmacokinetics and information for prescribing.
Gabapentinoids have an established evidence base for use in the treatment of non-cancer neuropathic pain, including diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain, comparable with antidepressants [15] [16] [17] [18] [19] [20] [21] . Recent Cochrane reviews of the management of neuropathic pain and gabapentinoids demonstrate a lack of studies investigating their use in cancer pain. No studies were identified for pregabalin use in acute and chronic pain in adults with cancer neuropathic pain [20] . Only three studies related to cancer pain management in a systematic review evaluating gabapentin in the management of chronic neuropathic pain in adults [21] .
TUMOUR-RELATED PAIN
The specific nature of pain is not always well defined, but most studies involve neuropathic or bone pain. Gabapentinoids have largely been evaluated in combination with other analgesics, but a few studies evaluate their use as monotherapy. For the purposes of this review, monotherapy was defined as the use of gabapentin/pregabalin alone with no other regular analgesic, adjuvant, or disease modifying treatment. Studies allowing 'as required' short-acting opioids as rescue medication were still classified as monotherapy studies as the overall daily consumption is often inconsistent and poorly defined. Combination therapy was defined as the use of gabapentin/pregabalin in combination with an alternative analgesic, adjuvant, or disease modifying treatment. Controls were either placebo or an alternative analgesic, adjuvant, or disease modifying treatment. Table 2 summarises and provides further detail about included tumour-related pain studies.
MONOTHERAPY STUDIES
In their open-label study, Raptis et al. [22] identified 120 patients with moderate-to-severe neuropathic cancer pain (NCP), uncontrolled on mild opioids. A total of 60 patients were randomised to pregabalin and 60 patients to transdermal fentanyl. In the pregabalin group, 73.3% achieved at least a 30% reduction in the visual analogue score (VAS) for pain, in comparison to 36.7% in the fentanyl group (P < 0.0001). Other statistically significant outcomes in favor of pregabalin were mean change in VAS score from baseline and final VAS score. This study shows some evidence of the benefit of pregabalin over fentanyl. It included patients with chemotherapy-induced neuropathy and tumor-related pain and the extent to which findings can be extrapolated to either group is unknown.
KEY POINTS
Gabapentinoids act by reducing pain transmission in spinal pathways and modulating central descending inhibitory pathways.
Statistically significant benefits using gabapentinoids as monotherapy or as part of combination therapies for tumour-related cancer pain have been found.
Many existing RCTs have poor methodology due to small sample size, lack of blinding, and insufficient follow-up to demonstrate full effect of interventions.
More RCTs of better quality are needed, although it may be challenging to accomplish in this patient population.
Gabapentinoids may offer benefits to cancer patients with pain, but careful titration and monitoring of adverse effects is necessary. CI, confidence interval; CIBP, cancer-induced bone pain; DAD, daily average dose; DN4, Douleur neuropathique 4 (questionnaire); ITT, intention to treat; MED, minimally effective dose; NCP, neuropathic cancer pain; NRS, Numerical Rating Scale; NSAID, non-steroidal anti-inflammatory drug; OME, oral morphine equivalent; VAS, visual analogue scale.
Mishra et al. [23] compared pregabalin with gabapentin, amitriptyline, and placebo in groups of 30 patients with severe NCP for 4 weeks. Results favoured pregabalin over all other groups with a reduction in mean VAS score from 7.77 to 2.5, and significantly lower scores in comparison with amitriptyline by week 3, and gabapentin and placebo by week 4. Scores were comparable at baseline and final VAS scores were 3.07, 3.23, and 3.4 for gabapentin, amitriptyline, and placebo, respectively. The pregabalin group also showed the greatest improvements in dysaesthesia, burning, and lancinating pain (statistically significant), but not allodynia. Gabapentin showed favourable outcomes over amitriptyline and placebo for burning and lancinating pain. However, there was no comparison of the differences between baseline and final outcomes. Therefore, the data are limited and it is unclear if pregabalin is superior.
COMBINATION THERAPY STUDIES
RCTs have evaluated gabapentinoids in combination with opioids alone and opioids in conjunction with both radiotherapy and antidepressants.
COMBINATION WITH OPIOIDS ALONE
In 2004, Caraceni et al. [24] reported on the first placebo-controlled study of gabapentin in combination with opioids for NCP. A total of 79 patients received gabapentin and 41 patients received placebo over 10 days. Both groups had comparable and stable opioid dosing ($100 mg/day oral morphine equivalent). Gabapentin combined with opioid showed lower global pain scores compared to placebo [4.6 vs. 5.4, respectively on 0-10 numerical rating scale (NRS)]. The proportion of patients with at least 33% reduction in pain showed more responders in the gabapentin group on day 1 (24 vs. 15%); however, by day 5 the group differences converged. There were no differences in common neuropathic pain symptoms and signs reported between the groups. In the gabapentin group, 70% of patients required the maximum daily dose (1800 mg), and one third still reported pain more than 5/10 on the final follow-up day. Although there is some evidence of additional benefit using gabapentin-opioid combination therapy, it may be minimal and offset by drugrelated adverse events.
In 2007, Keskinbora et al. [25] conducted an open-label study of gabapentin for NCP. A total of 75 patients were randomised to receive gabapentin and opioid or to continue on opioid therapy alone. The authors reported significantly lower mean pain scores after 2 weeks (compared to baseline) for both groups; however, the drop in pain scores was significantly greater for the gabapentin and opioid group. In contrast to Caraceni et al. [24] , Keskinbora et al. [25] demonstrated a clear therapeutic effect of gabapentin when used in combination with 140 mg/day oral morphine equivalent dose.
In an open-label study, Mercadante et al. [26] compared opioid monotherapy to a combination of opioid and adjuvant pregabalin in 70 advanced cancer patients with unclassified cancer pain. Over an 8-week follow-up period, there were no differences in pain intensity, medication side-effects, pain interference with daily activities, or quality of life between the two groups. The authors concluded that their flexible approach to dosing pregabalin, the small sample, and between group heterogeneity (pain cause and pain mechanisms) may account for the negative findings. Nevertheless, the doses of pregabalin used were much lower than other pregabalin studies and may reflect cautious prescribing.
Garassino et al. [27] compared two escalating strategies for pregabalin and oxycodone combination therapy for NCP in a multicentre RCT. A total of 38 patients were allocated to fixed oxycodone dose with increasing titration of pregabalin (group A); and 37 patients were allocated to fixed pregabalin dose with increasing titration of oxycodone. Followup was 2 weeks, after which 77% of patients in group A achieved at least 33% reduction in pain intensity (compared to baseline) vs. 64% in group B. The difference was not significant. There were fewer side effects and rescue doses for breakthrough pain reported in group A. The authors concluded that both titration strategies resulted in adequate pain relief and indicated a preference for a pregabalin titration strategy (group A), reasonable given the secondary outcomes.
Sjölund et al. [28] compared flexible-dose pregabalin with placebo, both in combination with stable opioid therapy in 152 patients with cancerinduced bone pain (CIBP). After 28 days follow-up, the mean change from baseline in worst pain score favoured pregabalin over placebo (-1.53 vs. -1.23). There were similar changes in average pain and sleep interference in favour of pregabalin. The frequency of side effects was higher in the pregabalin group compared with the placebo group. The authors did not undertake statistical comparisons on account of early termination of the trial due to positive effects in the pregabalin-opioid combination arm. Therefore, definitive conclusions cannot be drawn.
In 70 cancer patients with unspecified severe pain, Chen et al. [29] randomised patients to receive gabapentin in combination with oxycodone or oxycodone alone. The authors describe the primary outcome pain intensity on 0-100 mm VAS but no data are reported in the results. Baseline daily average oxycodone doses (DAODs) were not reported; however, at week 1 follow-up the DAOD was 23.4 and 25.3 mg/day for intervention and control groups, respectively. Between group differences in DAOD were not significant at week 1 or 1 month follow-up but were significantly different (in favour of gabapentin) at 3 and 6 month follow-up. Nevertheless, poor reporting of outcome measures and their results prevents meaningful interpretation of the study findings which should be interpreted with caution.
In a crossover study, Dou et al. [30 & ] evaluated the efficacy of pregabalin in combination with morphine. A total of 40 patients with severe NCP were randomised to receive pregabalin-morphine combination followed by morphine-placebo combination, or vice versa. The 2-week treatment periods were separated by a 1 week washout period. Mean minimally effective morphine dose was significantly lower during the pregabalin-morphine combination period (184.4 AE 69.9 mg/day) compared with the placebo-morphine combination period (228.7 AE 66.9 mg/day), with greater improvements in sleep and reduction in constipation (both significant) but higher rates of dry mouth and drowsiness. The authors concluded that equivalence pain relief can be achieved with lower dose of morphine following the addition of pregabalin treatment.
OTHER COMBINATION THERAPIES
Arai et al. [31] compared low-dose gabapentin in combination with imipramine, with low-dose gabapentin, high-dose gabapentin, and imipramine, all in combination with opioids in 52 patients with NCP. Some patients in all groups continued regular NSAIDs. The gabapentin/imipramine/opioid group's final total pain score was significantly lower than both the low-dose gabapentin/opioid and imipramine/opioid groups alone, but not the high-dose gabapentin/opioid group. However, the sample sizes were very small (n of [12] [13] [14] , NSAID and varying opioid use may have confounded the result, and 7 days of follow-up is unlikely to be sufficient to demonstrate full effect. There is insufficient evidence to support one intervention over another.
In their open-label RCT, Banerjee et al. [32] evaluated gabapentin in combination with tramadol vs. amitriptyline and tramadol in 88 patients with NCP over 6 months. Patients were excluded during the study if they used a stronger opioid. No statistical differences in VAS pain score, percentage of pain relief, and global pain score were found throughout the study period. Both groups improved overall with VAS score, with the most significant improvements in the first month; however, this is difficult to interpret without further information about the titration schedule. This study shows no benefit of gabapentin over amitriptyline when used in combination with tramadol. It is unclear if the findings can be extrapolated to populations requiring stronger opioids.
In 2016, Fallon et al. [33] , recruited 233 patients scheduled for radiotherapy with moderate-to-severe CIBP in five cancer centers. A total of 116 patients were randomised to pregabalin and 117 patients to placebo, both in combination with palliative radiotherapy and a regular opioid, for 4 weeks. There was no difference between proportion of each group achieving treatment response (defined as a reduction of at least two points in worst pain NRS from baseline, and stable/reduced opioid dose), average and worst pain, pain intensity and interference, or number of breakthrough episodes. The study was underpowered, given the dropout of study participants, and opioid use between groups was poorly described. However, this is an otherwise well-conducted study showing no evidence of additional benefit with pregabalin.
Nishihara et al. [34] also evaluated the use of pregabalin as a combination therapy in CIBP. A total of 12 patients were randomised to high-dose pregabalin (group 1). The two comparator groups had pregabalin at a lower dose with group 2 (12 patients) also given imipramine, and group 3 (13 patients) also given mirtazapine. All patients were given a regular opioid, an NSAID, and a bisphosphonate. Some patients in each group were also given paracetamol. Groups 2 and 3 both had statistically significant reductions in total pain score and daily paroxysmal pain episodes in comparison with the group 1 throughout the study period of 7 days. However, as the sample sizes are small with very short follow-up, the findings may not demonstrate the full effect. Therefore, this study's findings are inconclusive regarding the role of gabapentinoids in combination with antidepressants.
TREATMENT-RELATED PAIN
Gabapentin and pregabalin have both been evaluated in RCTs to prevent or manage treatmentrelated cancer pain. In this section, treatmentrelated pains are defined as pains arising from specific cancer treatments, such as chemotherapy and radiotherapy. Table 3 summarises and provides further detail about included treatment-related pain studies. We have not discussed cancer surgery and postoperative pain due to the crossover with mechanisms of pain in non-cancer postoperative pain. A Table 3 . Detailed summary of treatment-related pain studies. recent systematic review evaluating the use of preoperative gabapentinoids in patients undergoing breast cancer surgery found improvements in acute postoperative pain in comparison with patients receiving placebo/active controls [35] .
GABAPENTIN STUDIES
Rao et al. [36] used a crossover study to compare gabapentin with placebo in chemotherapy-induced neuropathic pain over a 3-week duration. No significant differences were found between gabapentin and placebo. However, the study was underpowered. Furthermore, eligible patients were those with pain, sensory loss, or paraesthesia. This approach might have lacked sensitivity to detect any analgesic efficacy. Kataoka et al. [37] evaluated the effect of gabapentin or placebo added to opioids and paracetamol in 22 patients with head and neck cancer with mucositis as a result of chemoradiotherapy. Higher pain scores and opioid doses were found in the gabapentin arm, but these were not significantly different from placebo. This was partly a feasibility study enabling data collection for future sample size calculations. It is very unlikely that the study was powered well enough to detect a possible difference.
PREGABLIN STUDIES
The effectiveness of pregabalin in preventing oxaliplatin-induced painful neuropathy was evaluated by de Andrade et al. [38] . Of 199 colorectal cancer patients who were pain free and chemotherapy naive randomized, 56 were subsequently excluded from analysis. Of those that were analyzed, 78 received pregabalin and 65 received control 3 days before and 3 days after each oxaliplatin infusion. Follow-up lasted up to 6 months post-chemotherapy. Average pain intensity and neuropathic pain symptoms assessed using the Douleur neuropathique-4 (DN4) and the neuropathic pain symptom inventory showed no differences between groups. This was corroborated by nerve conduction studies that also failed to show any protective effect of pregabalin.
Another smaller study evaluating the protective effects of pregabalin was conducted by Shinde et al. [39] . Patients who were about to receive paclitaxel chemotherapy were randomized to pregabalin or placebo. A total of 46 patients were recruited and no differences in pain intensity were found between arms.
CONCLUSION
For tumour-related pain, ten out of thirteen studies showed statistically significant benefits in favour of gabapentinoids. When used, as part of monotherapy or combination therapy, benefits were observed in five out of six studies evaluating gabapentin, and in six out of eight studies evaluating pregabalin. For treatment-related pain, none of the four studies (two gabapentin, two pregabalin) showed statistically significant benefits in favour of gabapentinoids. Unfortunately, many of the studies included were limited by small sample size, lack of blinding, and inadequate follow-up, considering the need to titrate treatments. This review is in agreement with systematic reviews within the last 5 years [40] [41] [42] [43] [44] . More and better quality studies are required, although it may be challenging to accomplish in this patient population. Gabapentinoids may offer benefits to cancer patients with pain, but careful titration and monitoring of adverse effects is necessary.
